Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Venlafaxine relieves anxiety; more cost-effective than other antidepressants

July 16, 1998

Lilly team claims metabotropic glutamate receptor antagonists

July 16, 1998

CNS compounds from ADIR that selectively bind to D4 receptors

July 16, 1998

Phase II clinical trial begins for fibromyalgia treatment

July 16, 1998

Risperidone: satellite symposia discuss impact on cognition and behavior

July 16, 1998

Pfizer reports pharmacokinetics of a novel anxiolytic agent - CP-93393

July 16, 1998

M-100907 improves positive and negative symptoms and is well tolerated in schizophrenics

July 15, 1998

Preliminary evidence of antidepressant effect for igmesine, a sigma ligand

July 15, 1998

Mitsui Toatsu describes potent, long-acting and orally bioavailable antipsychotic agents

July 15, 1998

CR-2945, a promising new anxiolytic agent in preclinical testing

July 15, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...